The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of prophylactic pegfilgrastim on day 3 of neoadjuvant DCF chemotherapy in elderly patients with resectable esophageal cancer.
 
Go Ikeda
No Relationships to Disclose
 
Yuri Yoshinami
No Relationships to Disclose
 
Toru Kadono
No Relationships to Disclose
 
Toshiharu Hirose
No Relationships to Disclose
 
Akihiro Ohara
No Relationships to Disclose
 
Mai Itoyama
No Relationships to Disclose
 
Ikuko Azuma
No Relationships to Disclose
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb Japan; Merck Sharp and Dohme; Ono Pharmaceutical
 
Yoshitaka Honma
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Eisai; Janssen
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; GlaxoSmithKline; Janssen; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical
 
Koshiro Ishiyama
No Relationships to Disclose
 
Jyunya Oguma
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)